Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children
Authors:
- 24 December 2014
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (4) , 674-679
Abstract
Background For children who experience a re-induction failure or multiple recurrences following the first relapse of acute lymphoblastic leukemia (ALL), it is uncertain whether additional intensive chemotherapy aimed at hematopoietic stem cell transplantation (SCT) in complete remission (CR) or immediate SCT even in non-CR should be performed. This study aimed to investigate the impact of disease status at SCT on the outcomes of SCT for these children, whose prognosis is considered unquestionably poor even with SCT. Procedure The medical records of 55 children with ALL who underwent SCT following the experience of re-induction failure (n = 25) or multiple relapses (n = 30) were retrospectively analyzed. Results Twenty-one patients underwent SCT in CR (delayed CR2, CR3, and CR4) and 34 in non-CR (first or subsequent relapse). The probability of overall survival of patients with CR and with non-CR at SCT was 42.9% and 23.5% (P = 0.15), leukemia-free survival was 38.1% and 20.6% (P = 0.18), and the cumulative incidence of relapse at 2 years was 23.8% and 50%, respectively (P = 0.05). In multivariate analysis, non-CR at SCT was a significant risk factor for higher relapse incidence and male sex was a significant risk factor for lower survival. Conclusions Our results indicated that in case of tolerable patient condition, further re-induction chemotherapy might be reasonable so that SCT could be performed in CR, which might result in a low incidence of relapse after SCT. Novel approaches are required to induce CR for the treatment of children with relapsed/refractory ALL. Pediatr Blood Cancer 2015;62:674–679.Keywords
This publication has 31 references indexed in Scilit:
- Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third RemissionTransplantation and Cellular Therapy, 2011
- Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study GroupEuropean Journal of Cancer, 2011
- Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction FailureJournal of Clinical Oncology, 2010
- Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium StudyJournal of Clinical Oncology, 2010
- Clofarabine, cyclophosphamide and etoposide as single‐course re‐induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemiaBritish Journal of Haematology, 2009
- Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot StudyJournal of Clinical Oncology, 2008
- Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison studyThe Lancet, 2007
- Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology GroupJournal of Clinical Oncology, 2005
- Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2005
- Treatment of isolated central nervous system relapse in high‐risk lymphoid malignancy with allogeneic bone marrow transplantation and extended intrathecal therapyBritish Journal of Haematology, 2004